FGFR2 and intrahepatic cholangiocarcinoma: The intervention was a guideline-based treatment regimen, namely, pemigatinib for patients with FGFR2 fusions/rearrangements and mFOLFOX (partially covered by NHI) for those without FGFR2 fusions/rearrangements, while the comparator was 5-FU, the most commonly used second-line regimen for Taiwanese patients with advanced ICC [12].